23.03.2020 kl 09:55 6686

6.3.2020, 13:36 · Cision
ExpreS2ion Biotechnologies: ExpreS2ion announces EU grant award for the COVID-19 vaccine development programme
Hørsholm, Denmark, March 6, 2020 - Today, ExpreS[2]ion Biotechnologies ApS ("ExpreS[2]ion"), a fully owned subsidiary of ExpreS[2]ion Biotech Holding AB, announces that the consortium has been awarded an EU Horizon 2020 grant for the COVID-19 (SARS-CoV-2) Coronavirus vaccine development programme. The award funding amounts to 2,7 MEUR (28MSEK), of which ExpreS[2]ion directly is funded with 0.88 MEUR (9.3 MSEK).
The aim of the grant is to support the consortium in development of a COVID-19 vaccine candidate, including performing a Phase I/IIa clinical trial. The ambitious aim is to initiate clinical investigations within 12 months.

The EU Horizon 2020 consortium members are world-leading experts in their respective fields, covering all relevant areas of viral research and vaccine development required for rapid clinical development of a COVID-19 vaccine. This includes pre-clinical and clinically validated experience from working with similar Coronaviruses such as MERS and SARS, ExpreS[2]ion's Drosophila S2 insect cell expression system, and AdaptVac's capsid virus-like particle (cVLP) technology.

ExpreS[2]ion's CEO Bent Frandsen comments:

"ExpreS[2]ion has since its announcement on February 6[th], 2020 of initiating a vaccine development programme against COVID-19 worked diligently to progress on its project, including setting up consortia of viral research and clinical vaccine experts, which together with our ExpreS[2 ]protein production platform and our joint venture AdaptVac's cVLP technology as core enabling technologies increase the likelihood of a unique vaccine with stronger and long lasting immune response. We are very proud of being part of this EU's Horizon 2020 award, that supports our ambitious timeline of initiating clinical investigations within 12 months."
Redigert 21.01.2021 kl 07:57

Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.